A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study.
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2012
At a glance
- Drugs Imiquimod (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Therapeutic Use
- Sponsors 3M Pharmaceuticals; Graceway Pharmaceuticals
- 31 Jan 2012 New trial record
- 16 Feb 2007 Last checked against ClinicalTrials.gov record.